Ft Tech Tonic

Gene and stem cell therapies have been touted as the next phase in the longevity movement, with promises to rejuvenate the body at the cellular level and reverse the effects of ageing. But, as the prospect of life extension moves into the mainstream, it presents big questions for society as a whole. Are we ready for a world where people live much longer lives?In this final episode, the FT’s Michael Peel and Hannah Kuchler dive into the tough moral questions at the heart of the longevity movement. Hannah speaks to the team at Fountain Life, a longevity clinic trying to bring stem cell therapy to the middle classes. We meet Daniel Ives, founder of gene therapy company Shift Bioscience, and Liz Parrish, who has self-experimented with gene therapies through her company, Biovia. Finally, Michael speaks to Arthur Caplan, the head of the ethics board of longevity fund, Hevolution.Free to read:From immortal jellyfish to elephants: scientists probe secrets of long-lived animalsInside the billion-dollar quest to live b